Comparative Pharmacology
Head-to-head clinical analysis: SUBLOCADE versus SUBOXONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUBLOCADE versus SUBOXONE.
SUBLOCADE vs SUBOXONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUBLOCADE contains buprenorphine, a partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. It binds to mu-opioid receptors, reducing cravings and withdrawal symptoms without producing full opioid effects, and blocks other opioids from binding due to high affinity.
Partial agonist at mu-opioid receptor and antagonist at kappa-opioid receptor; also antagonist at delta-opioid receptor.
300 mg subcutaneously every 4 weeks for the first 2 doses, followed by 100 mg subcutaneously every 4 weeks; maintenance dose may be increased to 300 mg every 4 weeks if tolerating lower dose.
Sublingual tablet: Initial dose 2-8 mg buprenorphine/0.5-2 mg naloxone on Day 1; target maintenance 12-16 mg/3-4 mg once daily; maximum 24 mg/6 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 43–50 days due to prolonged absorption from the depot; steady-state reached after 4–6 months of monthly dosing.
Buprenorphine: 37 hours (range 20-70) due to slow dissociation from mu-opioid receptors; norbuprenorphine: ~30 hours.
Primarily fecal (biliary) elimination of unchanged buprenorphine and metabolites; approximately 30% excreted in urine, mostly as conjugated metabolites.
Buprenorphine: ~70% fecal, ~30% renal. Norbuprenorphine: ~70% renal, ~30% fecal.
Category C
Category C
Partial Opioid Agonist
Partial Opioid Agonist/Naloxone Combination